Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
20 hedge funds and large institutions have $116M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
5% less funds holding
Funds holding: 21 → 20 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
40% less capital invested
Capital invested by funds: $195M → $116M (-$78.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.25M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.14M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$462K |
| 4 |
FO
FT Options
Chicago,
Illinois
|
+$200K |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$163K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.13M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$198K |
| 4 |
Millennium Management
New York
|
-$185K |
| 5 |
WT
Wellcome Trust
London,
United Kingdom
|
-$47.2K |
NBRV Hedge Fund Activity: Q1 2016 in Review
20 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q1 2016, worth a combined $116M — down 40% from $195M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NBRV and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $1.25M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $1.5M sold.
- 20 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q1 2016, down from 21 in Q4 2015.
- Funds reported $116M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q1 2016, down 40% quarter-over-quarter.
- 2 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q1 2016 and 3 closed out, a net change of -1 holder.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q1 2016 was Rock Springs Capital Management, an estimated $1.25M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q1 2016 was Sphera Funds Management, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2016.